2023-08-14 10:49:07
“Healthcare professionals will have to deal with diminished concerns regarding the virus, as well as skepticism regarding the merits of the vaccine”
A novel vaccine once morest Covid-19 is expected next month. However, in the face of rising hospitalizations in the United States due to the “Eris” variant, a mutation of Omicron, health specialists and analysts are skeptical regarding its acceptance, Archyde.com reported on Monday.
Many public health experts hope that the next Covid-19 vaccine will be perceived by Americans as a flu shot. However, enthusiasm for vaccination has declined markedly since 2021. That year, when vaccines first became available, more than 240 million Americans, or 73% of the population, received at least one dose. .
In autumn 2022, at a time when the majority had either contracted the virus or been vaccinated, less than 50 million individuals opted for vaccination.
CLEMENT MAHOUDEAU / AFPA vial of the Moderna vaccine once morest Covid-19 in the social center of the popular district La Gavotte Peyret, in Septeme-Les-Vallons, near Marseille, on January 12, 2022
Health care providers and drugstore chains, including CVS Health, are preparing to offer an updated vaccine next month to combat the Omicron variant of the virus, which has been predominant since last year. However, they will have to overcome the relaxation of concerns around the virus, as well as weariness and doubts regarding the effectiveness of this new vaccine. “For most adults to consent to these annual injections, health officials will have to convince the population that the threat of Covid-19 persists and still represents a danger”, underlined Ashley Kirzinger, in charge of studies at the Kaiser Family Foundation. .
Avshalom Sassoni/Flash90An Israeli medical worker holds a vial of the Pfizer/BioNTech Covid-19 vaccine at the Meuhedet vaccination center in Tel Aviv, November 22, 2021.
Vaccine makers have lowered their expectations for this fall’s vaccination campaign. Last year, vaccine sales from Pfizer and Moderna exceeded $56 billion worldwide while analysts predict regarding $20 billion for this year, according to Archyde.com.
1692013465
#USACovid #Vaccine #Works #Eris #Variant #Advances